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Edited by Angel NebredaAbstract The p53 tumour suppressor protein is a DNA-binding
transcription factor activated in response to DNA damage. Inac-
tivation of the p53 gene occurs in 40–60% of human tumours and
a substantial body of work indicates that loss of p53 activity is a
critical step in oncogenesis. p53 helps to protect against neopla-
sia by inducing death in cells that have sustained irreparable
DNA damage or by blocking cell cycle progression to allow time
for DNA repair. We have previously reported that p53 prevents
G2/M transition by decreasing intracellular levels of cyclin B1
protein and attenuating the activity of the cyclin B1 promoter
[S.A. Innocente, J.L. Abrahamson, J.P. Cogswell, J.M. Lee,
p53 regulates a G2 checkpoint through cyclin B1, Proc. Natl.
Acad. Sci. USA 96 (1999) 2147–2152]. The ability of p53 to con-
trol mitotic initiation by regulating intracellular cyclin B1 levels
suggests that a cyclin B1-dependent G2 checkpoint has a role in
preventing neoplastic transformation. Here, we show that p53-
mediated attenuation of the cyclin B1 promoter occurs in both
p21+/+ and p21/ cell lines. Furthermore, promoter attenuation
is dependent on the presence of functional Sp1 binding sites and
is independent of the NF-Y binding sites. We also ﬁnd that wild-
type, but not mutant, p53 protein binds Sp1 and the cyclin B1
promoter. This suggests that wild-type p53 mediates transcrip-
tional repression of cyclin B1 through the Sp1 transcription
factor.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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cycle1. Introduction
The eukaryotic cell cycle consists of sequential rounds of
chromosomal DNA synthesis (S) and chromosomal segregation
(M) separated by G1 and G2 gap phases. Transition between
cell cycle boundaries is under the control of the cyclin family
of proteins and the cyclin-dependent kinases (CDKs). Mamma-
lian cells have evolved regulatory mechanisms, termed check-
points, which prevent cell cycle transition after exposure to
DNA damage or other cellular stress [2]. Multiple, independent
checkpoints have been identiﬁed that prevent G1/S and G2/M*Corresponding author. Fax: +1 613 562 5452.
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tivation is a property of most, if not all, cancer cells [4].
Mitotic entry is under the control of the B-type cyclins [5].
Cyclin B functions by binding to the cdc2 kinase; the resul-
tant complex is termed the maturation promoting factor
(MPF). Cdc2 is non-functional without its cyclin B partner.
Control of cyclin B1/cdc2 abundance and activity at multiple
levels ensures correct mitotic timing [6]. Cdc2 kinase activity
is inhibited by phosphorylation at Y15 and T14 residues;
wee1 phosphorylates and cdc25C dephosphorylates these res-
idues [7]. The human cyclin B1 gene is initially activated in
S-phase and its activity peaks at G2/M [8]. The human cy-
clin B1 promoter contains several cis-elements that allow cell
cycle-speciﬁc expression. These elements include binding sites
for the transcription factors USF [9], NF-Y [10], MyoD,
Ap-2 and Sp1 [11]. We have previously shown that the
p53 tumour suppressor activates a G2/M checkpoint by
repressing cyclin B1 promoter activity [1]. However, the
mechanism responsible remains to be full elucidated. The
p53 protein is a transcription factor that binds to DNA in
a sequence-speciﬁc fashion to activate transcription of target
genes. The consensus DNA-binding sequence for p53 con-
sists of two repeats of the 10 bp motif 5 0-PuPuPuC(A/
T)(A/T)GPyPyPy-3 0 separated by 0–13 bp [12]. Activation
of p53 by cellular stresses such as DNA damage, hypoxia
and oncogene activation leads to the induction of cell cycle
arrest or apoptosis. Transactivation of the p53 target genes
p21, GADD45 and 14-3-3 is involved in mediating cell cycle
arrest by p53 [13–16]. The p21 protein inhibits DNA synthe-
sis by inactivating the CDKs necessary for G1/S transition.
Up regulation of 14-3-3r by p53 is thought to inhibit mito-
sis by attenuating the nuclear transport of cyclin B1 [17].
In addition to activating transcription, p53 is also able to
repress transcription from various promoters. Transcrip-
tional repression by p53 has been shown be important for
the promotion of apoptosis [18]. Targets of p53 repression
include cyclin B1, b-tubulin, Map4, survivin, AFP and
POLD1 genes [1,19–23]. Here, we report that p53 can re-
press cyclin B1 transcription through the transcriptional acti-
vator Sp1. Mutation of both the 5 0 and 3 0 Sp1 binding sites
in the cyclin B1 promoter abrogated the repression eﬀect of
p53, whereas mutation of both the 3 0 and 5 0 NF-Y binding
sites had little eﬀect. We also found that wild-type, but not
mutant, p53 interacts with Sp1 and the cyclin B1 promoter.
These observations are consistent with the idea thatblished by Elsevier B.V. All rights reserved.
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p53 with Sp1 bound to the cyclin B1 promoter.2. Materials and methods
2.1. Cell culture and cell lines
Saos-2 and SKOV-3 were purchased from the American Type Cul-
ture Collection (ATCC, Manassas, VA) and cultured in McCoys 5A
medium supplemented with 10% FBS and 2% antibiotic–antimycotic
(Invitrogen, Burlington, ON). The HCT-116 (p21+/+) and HCT-116
(p21/) were a gift of Dr. Bill Taylor (The Cleveland Clinic, Cleve-
land, OH) with permission from Dr. Bert Vogelstein (Howard Hughes
Medical Institute, Baltimore, MD). HCT-116 cells were maintained in
DMEMwith 10% FBS and 2% antibiotic–antimycotic. Ts-SKOV3 was
a kind gift of Dr. Massimo Broggini and is a derivative of the parental
SKOV3 ovarian cancer line and details of its construction are found
elsewhere [24]. For recombinant protein production, Sf9 cells (Spodop-
tera frugiperda, ATCC) were grown in Graces Insect Medium with L-
glutamine (Invitrogen) and supplemented with 10% yeastolate and
10% heat-inactivated FBS and cultured at 28 C.
2.2. Plasmid constructs
The 1050 and 287 cyclin B1 promoter sequences were gifts of Drs.
John Cogswell (Glaxo Research Institute, NC) and Karen Katula
(University of North Carolina, Greensboro, NC), respectively, and
have been described previously [9,10]. The 1050 and 287 luciferase pro-
moter reporter construct were created by cloning either the 1050 or 287
fragments into the KpnI and HindIII sites in the pGL3-Enhancer lucif-
erase reporter vector (Promega, Madison, WI). The Sp1 binding site
mutants (287cycB1-3 0-Sp-1, 287cycB1-5 0-Sp-1, and cycB1-3/5-Sp-1)
were generated via PCR using the following primers 5 0-Sp1-Mut-R
(5 0-GTGCGCCCAACACCTGG-3 0) and 3 0-Sp1-Mut-R (5 0-CGA-
GAGGTTGGGGGCCA-3 0). The p53 expression plasmid was derived
by cloning the human wild-type p53 cDNA into the XbaI/EcoRI sites
in pCDNA3 (Invitrogen) and was a kind gift of Dr. Carol Prives
(Columbia University, New York, NY). The Sp1 expression plasmid
was a kind gift of Dr. Anil Rustgi (University of Pennsylvania, Phila-
delphia, PA) and its construction has been described elsewhere [25].
The sequences of all plasmid constructs were veriﬁed by automated
DNA sequencing by the Institute of Molecular Biology (MOBIX) at
McMaster University.
2.3. Transient transfection and luciferase reporter gene assays
SKOV-3 and Saos-2 cells were seeded at 1.5 · 105 cells per well in 6-
well plates and grown overnight in growth medium. Cells were trans-
fected with 1 lg of p53 expression plasmid or control pcDNA3 plasmid
and 3 lg of pGL3 reporter constructs using GenePorter I (Gene Ther-
apy Systems, San Diego, CA) according to the manufacturers protocol
at a DNA/reagent ratio of 1:5. Three hours post-transfection, the med-
ium was changed and fresh growth media was added. For luciferase as-
says, cells transfected in six-well plates were washed three times with
2 ml of ice-cold PBS. Cells were lysed in 200 ll of lysis buﬀer (1%
(vol/vol) Triton X-100, 25 mM glyclglycine, pH 7.8, 15 mM MgSO4,
4 mM EGTA, and 1 mM DTT). Samples were assayed in a Tropix
TR717 multiwell luminometer using 70 ll cell lysate, 175 ll assay buf-
fer (25 mM glyclglycine, pH 7.8, 15 mM MgSo4, 4 mM EGTA, 2 mM
ATP, and 1 mM DTT) and 140 ll of luciferin (1 mM luciferin in
25 mM glyclglycine, pH 7.8, and 10 mM DTT). Luciferase activity
was measured a 10 s delay and 20 s integration time and normalized
to the protein concentration of each sample.
2.4. Western blotting and immunoprecipitation
Cells were lysed in RIPA (25 mM Tris, pH 8.2, 50 mM NaCl, 0.1%
SDS, 0.5% Nonidet P-40 and 0.5% deoxycholate) buﬀer with protease
inhibitors. Proteins were resolved on SDS–PAGE gels and transferred
to nitrocellulose via semi-dry transfer (BioRad). Immunoblots were
blocked in 5% milk in TBST for 1 h and washed three times with fresh
TBST. Primary antibodies were incubated with immunoblots for 1 h at
room temperature and washed three times with fresh TBST. Similar
concentrations of secondary antibodies were incubated with immuno-
blots for an additional hour at room temperature. Proteins were de-
tected using ECL-plus (Amersham Scientiﬁc) and a phosphorimager(GeneStorm 860, Molecular Dynamics). The p53 primary antibody
PAb 246 and the p53 Western Blotting kit were purchased from
EMD Biosciences (San Diego, CA). The Sp1 monoclonal antibody
E-3 was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). For immunoprecipitations, 100 lg of whole cell lysate was incu-
bated with 2 lg of antibody at 4 C with gentle rocking overnight.
20 ll (packed volume) of protein G Sepharose beads (Invitrogen) were
added and samples were incubated at 4 C with gentle rocking for 1 h.
Immunoprecipitates were collected via centrifugation and washed
three times with lysis buﬀer. Samples were resuspended in 2· loading
buﬀer, boiled for 5 min and subjected to SDS–PAGE.
2.5. Chromatin immunoprecipitation assays
Ts-SKOV-3 cells were grown in 150 mm plates and then transferred
to a 32 C incubator for 12–14 h. Cells were cross-linked with formal-
dehyde (1%) for 10 min on a rocking platform at room temperature.
Cross-linking was stopped following the addition of glycine (ﬁnal con-
centration of 125 mM) at room temperature for 5 min. Cells were
washed three times with ice-cold PBS and then scraped into 1 ml of
PBS containing protease inhibitors and pelleted at 700 · g. Cell pellets
were resuspended in 1 ml lysis buﬀer (5 mM PIPES, pH 8.0, 85 mM
KCl, and 0.5% NP-40) with protease inhibitors and incubated on ice
for 10 min. Nuclei were pelleted and resuspended in nuclear lysis buﬀer
(50 mM Tris, pH 8.1, 10 mM EDTA, and 1% SDS) with protease
inhibitors and incubated on ice for 10 min. Chromatin was sonicated
for a total of 3 min per sample (20 s bursts followed by 1 min on ice)
in a Branson Soniﬁer 250 with a 5 mm microtip. Samples were diluted
ﬁvefold in dilution buﬀer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris, pH 8.1, and 16 mM NaCl with protease inhib-
itors). Samples were pre-cleared with 60 ll of protein A agarose for 1 h
at 4 C. Samples were incubated with of either 5 lg of p53 PAb 421
(Oncogene Science) or Sp1 E-3 (Santa Cruz Biotechnology) or with
no antibody overnight at 4 C. Immune complexes were collected with
60 ll of protein A and washed once with 1 ml low salt buﬀer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8.1, and
150 mM NaCl), once with 1 ml high salt buﬀer (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris, pH 8.1, and 500 mM NaCl), once
with 1 ml LiCl buﬀer (0.25 mM LiCl, 1% NP-40, 1% deoxycholate,
1 mM EDTA, and 10 mM Tris, pH 8.0) and twice with 1 ml TE buﬀer.
Samples were then subjected to PCR. Samples were eluted with fresh
elution buﬀer (1% SDS, 0.1 M NaHCO3), DNA-protein cross-links
were reversed by incubation at 65 C and 5 M salt. Proteins were di-
gested with proteinase K and DNA was puriﬁed using QIAquick spin
columns as per manufacturers protocol. DNA was analyzed via PCR
using the following primers: ChIP forward 5 0-AGAGGCAGACCA-
CGTGAGA-30 and ChIP reverse 5 0-TTCCTCTTCACCAGGCAG-
CA-3 0.
2.6. Electrophoretic mobility shift assays
EMSA assays were conducted as follows, 2 ll of 5· EMSA buﬀer
(20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM
NaCl, 50 mM Tris–Cl, pH 7.5, and 0.25 mg/ml poly (dI-dC)), 25 ng
of 5 0-labeled 287 cyclin B1 probe, 300 ng of recombinant human Sp1
or p53 protein (Promega) and dH2O to 10 ll. Reactions were incu-
bated at room temperature for 30 min and samples to be super shifted
were incubated a further 30 min with 5 lg of anti-Sp1 (E6, Santa Cruz
Biotechnology) or anti-p53 (PAb 421, Oncogene Science) antibody.
Samples were then carefully loaded onto a pre-run 0.5· TBE 4% native
PAGE gel with an 80:1 (acrylamide:bisacrylamide) ratio. Flanking
lanes of bromophenol blue loading dye was loaded onto the gel to
monitor progress. The gel was run at a constant current of 25 mA until
the bromophenol blue dye-front was three quarters down the gel. The
gel was subsequently dried and exposed to a phosphorimager screen.3. Results
3.1. The human cyclin B1 promoter is negatively regulated in a
p53-dependent manner
To determine the eﬀect of ectopic expression of p53 on tran-
scription of the human cyclin B1 promoter, we transiently
transfected the p53-null cell lines Saos-2 and SKOV3 with
S.A. Innocente, J.M. Lee / FEBS Letters 579 (2005) 1001–1007 1003human cyclin B1 promoter luciferase vectors pGL3-1050 wt
and pGL3-287 wt and an expression vector for wild-type hu-
man p53 (pcDNA3-p53 wt). We have previously used both
Saos-2 and SKOV3 to study transcriptional repression by
p53 [1]. The pGL3-1050 wt and pGL3-287 wt reporter con-
structs contain the ﬁrst 1050 and 287 bp, respectively, of the
human cyclin B1 promoter 5 0 to the transcriptional start site
as determined by Cogswell et al. [9]. As shown in Fig. 1A
and B, ectopic expression of wild-type p53 decreases the activ-
ity of both the 1050 and 287 cyclin B1 promoter fragments
in SKOV3 and Saos-2 cell lines. In SKOV3, p53 repressed
1050- and 287 promoter activity 20-fold and 10-fold, respec-
tively. In Saos-2, p53 repressed 1050 activity threefold, and
287 ﬁvefold. Repression of both the 1050 and 287 constructs
by wild-type p53 indicate that the cis-repressible elements must
lie within the 287 region.
3.2. p53-dependent repression of cyclin B1 transcription does not
require p21
Previously, it has been shown that induction of p21 was re-
quired for p53-mediated repression of cdc2 transcription [26].
To determine whether p21 was required for repression of cyclinSKOV3
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Fig. 1. p53 is a p21-independent repressor of cyclin B1 transcription. (A) Ecto
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3 0 and 5 0-NF-Y sites in Saos-2 cells. All data points are expressed as percent
and represent the mean of three independent experiments together with stanB1, we used the colorectal carcinoma cell line HCT-116 that
expresses p21 (HCT116-p21+/+) and a variant that has no
p21 (HCT116-p21/). As shown in Fig. 1C, the presence or
absence of p21 expression had no eﬀect on p53-mediated tran-
scriptional repression of cyclin B1 (Fig. 1C). In both cell lines,
p53 inhibited 287 promoter activity 2.5-fold. While the ability
of p53 to repress cyclin B1 is reduced in HCT-116 compared to
SKOV3 and Saos2, the magnitude of repression is not changed
between the p21+ and p21 HCT-116 variants. This suggests
that the p53-mediated transcriptional repression of the cyclin
B1 promoter is independent of p21. Moreover, Saos-2 cells
have no Rb [27] and therefore repression of cyclin B1 by p53
is also independent of Rb.
3.3. Mutation of the CCAAT boxes has no eﬀect on
p53-mediated inhibition of cyclin B1 transcription
Induction of cyclin B1 transcription in the G2 phase of the
cell cycle is dependent in part on the binding of the NF-Y tran-
scription factor to the CCAAT sequence within the promoter
[10]. It has previously been reported that mutation of NF-Y
binding sites in the cyclin B1 promoter ablated p53-mediated
transcriptional repression senescing human ﬁbroblasts [28].Saos-2
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tested cyclin B1 promoter variants lacking both identiﬁed NF-
Y binding sites. As shown in Fig. 2A and B, overall levels of
p53-dependent repression of the promoter remained the same
between the wild-type promoter and the NF-Y single
(3 0CCAAT or 5/CCAAT) or double (3 0/5 0 CCAAT) mutants.
All constructs were repressed approximately 4–5-fold in both
SKOV3 and Saos-2 cells. p53 expression levels were similar be-
tween transfections as conﬁrmed by Western blot (not shown).
Since mutation of both the CCAAT boxes in the human cyclin
B1 promoter have no eﬀect on transcriptional repression by
p53, we conclude that NF-Y is not involved in p53-mediated
control of cyclin B1 promoter activity.A
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p53
The human cyclin B1 promoter contains a number of tran-
scription factor binding sites in addition to NF-Y, among
them USF, MyoD1 sites, an E2F site and Sp1 sites [29]. To
determine whether Sp1 was involved, we mutated Sp1 binding
sites. Sp1 binds to its consensus sequence 5 0-GGCGG-3 0 and
there are two such motifs in the cyclin B1 promoter, one begin-
ning at 259 and another at 140, relative to transcription
start. These sites were mutated singly and in tandem. As shown
in Fig. 3A, mutation of either the 3 0- or the 5 0-Sp1 sites re-
sulted in constructs that were still repressible by wild-type
p53. Each of the single mutants was repressed 4–5-fold by- + - + - +
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the 3 0 and 5 0 Sp1 sites resulted in complete abrogation of
repression (Fig. 3A). As shown in a single representative tran-
sient co-transfection experiment (Fig. 3B), Sp1 mutation re-
duced absolute activity of the construct as measured by raw
luciferase activity, but this reduction was still substantially
above background to detect p53-dependent transcription
repression. We observed an increase in p53-dependent activity
of the double Sp1 mutant in SKOV3 cells. The mechanism for
this is currently unknown. To further clarify and extend these
observations, we next determined whether ectopic expression
of Sp1 could aﬀect p53-mediated repression. As shown in
Fig. 3B and C, expression of Sp1 in the presence of p53 al-
lowed for nearly wild-type cyclin B1 promoter activity. These
results suggest that Sp1 may have an important role in p53-
mediated control of cyclin B1 transcription.
3.5. p53 interacts with Sp1 in vivo
We next investigated whether p53 could bind to Sp1. To that
end, we infected Sf9 cells with baculovirus expressing human
p53 and Sp1 constructs. As shown in Fig. 4A, wild-type p53
and Sp1 reciprocally co-immunoprecipitate in Sf-9 cells (Fig.
4A). To test whether Sp1 binds to either wild-type or mutant
p53, can measured p53/Sp1 co-immunoprecipitation in the
Ts-SKOV3 cell line. Ts-SKOV3 is a human cell line that stably
expresses a copy of the mouse p53 mutant allele p53val135. At
37 C the p53val135 protein has a mutant conformation but
adopts a wild-type conformation and function at 32 C [24].
Using Ts-SKOV3, we ﬁnd that there is little Sp1/p53 interac-
tion when p53 is in its mutant conformation (37 C) but there
is substantial interaction with both the 95 and 106 kDa forms
of Sp1 when p53 is in the wild-type (32 C) conformation (Fig.
4B). There are no detectable changes in the levels of p53 pro-Fig. 4. p53 and Sp1 interact in vivo. (A) Baculovirus-expressed human
p53 and Sp1 immunoprecipitate in Sf9 cells. (B) In Ts-SKOV3 cells
grown at 32 C, wild-type p53 co-immunoprecipitates strongly with
both the 95 and 106 kDa Sp1 proteins at 32 C and only very weakly at
37 C (top panel). p53 protein can be detected in the Ts-SKOV3 cells at
either 32 or 37 C (lower panel).tein in cells grown at 32 C versus 37 C (Fig. 4B, bottom).
Thus, both p53 and Sp1 physically interact but this interaction
preferentially occurs with wild-type p53.
3.6. p53 and Sp1 can interact with the human cyclin B1 promoter
To test if p53 and Sp1 can interact with the cyclin B1 pro-
moter in vivo, we conducted chromatin immunoprecipitation
(ChIP) assays using the Ts-SKOV3 cells described above.
PCR primers were designed to speciﬁcally amplify the region
of the human cyclin B1 promoter containing both Sp1 DNA-
binding sites. As shown in Fig. 5, Sp1 is found on the cyclin
B1 promoter at both 37 and 32 C temperatures (Fig. 5). This
suggests that the switch from the mutant to the wild-type p53
conformation between 37 and 32 C does not result in Sp1 dis-
sociation from the cyclin B1 promoter. On the other hand, p53
is interacts with the cyclin B1 promoter at 32 C but is only
poorly detected at 37 C. The low levels of cyclin B1 promoter
PCR products at 37 C is most likely a result of cross-linking
at 23 C and the high sensitivity of the ChIP technique. These
data indicates that p53 interacts with the cyclin B1 promoter
primarily in its wild-type conformation.
To determine whether p53 directly bound the cyclin B1 pro-
moter, we used EMSA assays to measure direct binding of p53
and Sp1 to the 287-promoter fragment. As shown in Fig. 5B,
the Sp1 protein can interact with the 287 fragment, as mea-
sured by a retardation of 287 mobility. A Sp1 antibody furtherFig. 5. p53 and Sp1 interact on the cyclin B1 promoter. (A) Sp1
protein can immunoprecipitate the cyclin B1 promoter at either 32 or
37 C, whereas p53 immunoprecipitate the cyclin B1 promoter very
weakly at 37 C (mutant conformation) and strongly at 32 C (wild-
type conformation). The total chromatin input (1:300 dilution) control
was used as a positive control. The no antibody control showed no
bands at either 37 or 32 C. (B) Sp1, but not p53 interact directly with
the 287 promoter fragment in an EMSA assay. Sp1 retards the
mobility of the 287 probe and this retardation can be increased with a
Sp1 antibody. Neither p53 protein nor p53 antibody retards 287
mobility with or without Sp1.
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does not detectably interact with the 287 promoter, nor does
it interfere with Sp1 biding. This suggests that the p53 protein
does bind the cyclin B1 promoter directly. Furthermore, there
is no consensus p53 binding site within the cyclin B1 promoter.
Since we observe that only wild-type p53 interacts with Sp1,
our data is consistent with a model where p53 inhibits cyclin
B1 transcription by interacting with promoter-bound Sp1
rather than the promoter itself, thereby blocking its ability to
transactivate cyclin B1.Fig. 6. Hypothetical mechanism for Sp1-dependant p53-mediated
cyclin B1 transcriptional repression. p53 interacts with the DNA-
bound transcriptional activator Sp1 and interferes with the recruitment
of the general transcriptional machinery and thus, results in repression
of cyclin B1 transcription.4. Discussion
In this report, we have investigated the role of the tumour
suppressor protein p53 in regulating cyclin B1 expression.
We ﬁnd that p53-mediated repression of the cyclin B1 pro-
moter is dependent on Sp1 binding sites and that Sp1 expres-
sion can rescue the p53-dependent cyclin B1 repression.
Furthermore, Sp1 can co-immunoprecipitate with wild-type,
but not mutant, p53. p53-mediated repression of cyclin B1 is
independent of p21 and NF-Y. Thus, our data are consistent
with the idea that p53-mediated repression of cyclin B1 is likely
to involve Sp1.
p53 has previously been shown to repress cyclin B1 tran-
scription in several cell types [30–32]. Taylor et al. have pro-
posed that p53 can repress cdc2 transcription via the
induction of p21WAF1 which in turn enhances the binding
of p130 and E2F4 to the cdc2 promoter to repress it. In our
hands, p53 can repress cyclin B1 transcription in both p21+/+
and p21/ cells, indicates that p21 is not absolutely required
for cyclin B1 repression. It is likely, therefore, that there are
p21-dependent and -independent pathways of repression.
In this report, we ﬁnd that NF-Y does not seem to be critical
in repression of cyclin B1 as mutation of both CCAAT sites in
the cyclin B1 promoter still allowed the construct to be re-
pressed p53 in both SKOV3 and Saos-2 cells. This issue is con-
troversial as other reports suggest NF-Y may be important for
p53-mediated cyclin B1 repression during senescence [28,30].
However, other data from Taylor et al. [29] have shown that
p53-mediated repression of cyclin B1 requires regions 287
to 123 of the promoter. This region does not contain any
NF-Y binding sites but does contain the distal Sp1 site, lending
further support to our idea that Sp1 and not NF-Y is the
important transcriptional activator mediating cyclin B1 tran-
scriptional repression by p53.
Our results have shown that the mutation of the transcrip-
tional activator Sp1 binding sites in the cyclin B1 promoter
completely abolished the p53-mediated repression of cyclin
B1 transcription. This repression requires the co-operation of
both the proximal and distal Sp1 sites as mutation of either
Sp1 site alone still conferred repression by p53. p53 has previ-
ously been shown to repress transcription from the HIV-LTR
[33], the POLD1 [23] and hTERT [34,35] genes through Sp1.
As there are no consensus p53-binding sites in the human cy-
clin B1 promoter and we were unable to detect p53 interaction
using an EMSA assay, it seems unlikely that p53 mediates
repression through direct DNA binding. We have shown that
wild-type p53 can immunoprecipitate with Sp1 and that both
proteins can be detected in the vicinity of the cyclin B1 pro-
moter. Mutant p53 does not interact with the Sp1 proteinand interacts very poorly with the cyclin B1 promoter. This
suggests that p53 mediates cyclin B1 repression through a pro-
tein-protein interaction with DNA-bound Sp1 protein (Fig. 6).
It is possible that this p53–Sp1 interaction interferes with the
downstream recruitment of the TFIID general transcriptional
machinery complex or other transcriptional activators. Thus,
our results show that p53 can function as a Sp1-dependent
inhibitor of cyclin B1 transcription, suggesting an important
role for p53 tumour development.
Sp1 can function as a dual activator and repressor of tran-
scription. As such, interaction between p53 and Sp1 does not
always lead to transcriptional repression. It has previously
been reported that interaction between p53 and Sp1 leads to
activation of p21 gene transcription [36]. In the case of p21
transactivation, p53 binding to Sp1 displaces HDAC1 from
Sp1 and increases p21 promoter activity concomitant with his-
tone hyper-acetylation at the p21 promoter [37]. Conversely,
transcriptional repression can be achieved by disconnecting
communication between Sp1 and the general transcriptional
machinery [38]. We postulate that p53 interferes with Sp1-
dependent recruitment of the general transcriptional machin-
ery to the cyclin B1 promoter and therefore reduces the levels
of cyclin B1 transcription. Alternatively, it is possible that the
p53–Sp1 complex could be a signal for the recruitment of
repressor complexes, including histone deacetylases, to the cy-
clin B1 promoter to repress transcription. Further character-
ization of the mechanism by which Sp1 regulates cyclin B1
transcription will be necessary to address this issue.
The overexpression of cyclin B1 in a number of carcinomas
[39–42] raises the possibility that a failure to control cyclin B1
promoter activity by p53 may be a prerequisite for tumour
growth. Future work in our lab will further investigate the
mechanisms involved in the p53-mediated repression of cyclin
B1 transcription.
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